Cassava Sciences | PTIE - Ebit


Cassava Sciences reported $-11.86M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Abbott USD 2.54B 358M Dec/2025
Amgen USD 4.43B 2.17B Sep/2025
Biogen USD 659.6M 157M Sep/2025
Cassava Sciences USD -11.86M 33.53M Sep/2025
Eisai JPY 13.67B 7.07B Sep/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Geron USD -13.89M 1.43M Sep/2025
J&J USD 5.11B 2.3B Dec/2025
Merck USD 7.56B 1.19B Sep/2025
Novartis USD -9.19B 13.87B Jun/2025
Pfizer USD 4.57B 1.97B Sep/2025
Roche Holding CHF 9.56B 2.1B Dec/2025